European Commission Approves Gilead's Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Portfolio Pulse from Happy Mohamed
The European Commission has approved Gilead Sciences' Trodelvy for the treatment of pre-treated HR+/HER2- metastatic breast cancer. The approval is based on the Phase 3 TROPiCS-02 study, which showed a statistically significant and clinically meaningful overall survival benefit of 3.2 months versus comparator single-agent chemotherapy. Trodelvy also demonstrated a 34% reduction in risk of disease progression or death.
July 27, 2023 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The approval of Trodelvy by the European Commission could potentially increase Gilead's market share and revenues in the European market. The positive results from the Phase 3 study could also boost investor confidence in the company.
The approval of Trodelvy by the European Commission opens up a new market for Gilead, potentially leading to increased sales and revenues. The positive results from the Phase 3 study could also boost investor confidence in the company's research and development capabilities, potentially leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100